Improving science into business
Scienness offers investment evaluation and technical analysis services, advises on the strategic evolution of projects and developments in the health sector, promotes the incorporation of health as a strategic vector in the service offering of other sectors and designs and implements sustainability and Enviromental health.
INVESTMENT
- Analisys of global investment trends
- Identification of investment opportunities
- Preliminary technical evaluation
- Technical investment audit
- Technical investments´ monitoring
- Permanent technical advise to research & investment teams
BUSINESS EVOLUTION
- Analysis of global trends in technical-scientific development
- Portfolio evaluation according to scientific trends
- Analysis and development of new products
- Regulatory Strategy
- Plant visit – Facilities Technical Audit
- GMP/GDP updates
- Permanent technical advice to management and consulting teams
SCIENCE FOR ALL
- Scientific advising for tenders
- Advice on new regulations and new health technologies
- Incorporation of science and health elements for competitive differentiation
- Analysis of models, trends and intersectoral applicability
- Permanent technical advice to management teams
SUSTAINABILITY & ENVIROMENTAL HEALTH
- Strategic advice on sustainability
- Carbon and water footprint assessment
- Waste management strategies
- Technology development for environmental health
- Supply chain and circularity
- Sustainable finance
It´s time to incorporate science into investment strategy and business evolution
FAQ´s
1. WHY INVEST IN HEALTH?
Assuming that four main investment megatrends for the next decade are concentrated in the areas of energy and demographic transformation, new consumption models, sustainability and technological innovation, investment in health has consolidated in recent years as one of the sectoral investments that have concentrated the most profitability and growth, due to the relationship of companies and business models in the health sector with most of the aforementioned investment megatrends. The confluence of structural changes at the global level, such as the increasing longevity of the world population; The growing fear in the post-covid era of future potentially pandemic horizons derived from the growing socio-economic globalization, that promotes the incorporation of the health vector in other economic sectors (tourism, transport, distribution, etc.); The confluence of global health scenarios in which high prevalences of pathologies typical of rich countries, coincide with a growing demand for health services and infrastructures in developing countries, are some of the factors that explain the exponential growth in the demand for assistance. and health services, the multiplication of spending and public-private investment, the increase in companies that operate in the sector and the improvement in the profitability of the sector in general and of the majority of those companies in particular.
Without considering technological investment related to health, global health spending accounts for around 10% of world GDP and will clearly increase. According to Morgan Stanley, in the last months of 2022, 343,000 million entered investment funds throughout Europe. Of these, some 80,000 million were invested in sectoral funds. Analyzing in depth the destination of these investments, it is verified that, in the first place, the investments were directed towards technological funds, followed by investment in health.
Undoubtedly, investing in health is today one of the investment options that can offer the best and most secure profitability in the medium/long term.
2. WHICH ARE THE LATEST TRENDS IN PHARMA INDUSTRY?
The pharma industry is facing a multitude of challenging trends: new work expectations, geopolitical considerations, rising inflation, supply chain disruption, advance in digital technology and user willingness, environmental, governance and social expectations. Pharma companies are experiencing a wave of innovations – from new treatment modalities, to smart machines, advanced analytics, and digital connectivity.
The product landscape also is changing swiftly. New modalities, such as cell and gene therapy and mRNA vaccine technology, have increased from 11 to 21 percent of the drug development pipeline—the fastest growth ever seen in the sector. Focusing on innovation as a lifesaver rather than on its cost, risks or relationship to
pharmaceutical company margins has been particularly clear in the largely unconditional excitement generated by mRNA technology. Within the area of vaccine development, mRNA offers the advantages of speed, adaptability and specificity. This technology also promises to transform other infectious diseases, including influenza and cytomegalovirus, as well as indications such as heart failure.
On the other hand, monoclonal antibodies (mAbs) are reliable warhorses that have revolutionised the treatment of a range of conditions, including cancer, cardiovascular, inflammatory and
infectious diseases. Although they have been on the market for more than 30 years, mAbs continue to be a mainstay of the pharmaceutical market’s dominant biologics segment, particularly in treating cancer and rheumatoid arthritis.
New applications for mAbs carry the promise of significant therapeutic advances in tackling truly global health challenges. But for that to happen, access and affordability will need to be part of the conversation, be it through manufacturing efficiencies, accelerated registration in low-income countries, genericization, differential pricing or voluntary licensing.
If you want to be part of this challenging future, a carefully evaluation of the technical and regulatory framework should be done.